Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis

Leukemia volume 32, pages 553–555 (2018)Cite this article

Subjects

Accurate disease risk assessment is crucial for treatment decision making in myelofibrosis (MF), with this particularly applying to younger patients who might be candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT).1, 2 For such purpose, several prognostic models are widely used in clinical practice.3, 4, 5 Though these models were derived from patients with de novo or primary MF (PMF), they are also applied to patients with MF secondary to essential thrombocythemia (PET MF) or polycythemia vera (PPV MF), despite data suggesting a poorer prognostic accuracy in this setting.6, 7 Recently, Passamonti et al.8 have developed a new prognostic model to specifically address the prediction of survival in patients with secondary MF, the Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM). It is worth noting that this prognostic model has not yet been tested in an independent series of patients.

We aimed to investigate the performance of the MYSEC-PM, as compared with the International Prognostic Scoring System (IPSS),3 in a nationwide series of 262 patients with secondary MF from the Spanish Registry of Myelofibrosis. We did not test the dynamic IPSS (DIPSS) and DIPSS-plus prognostic models as comparators because the former was optimized for prognostication during disease’s evolution whereas the second requires cytogenetic examination that is lacking in many MF patients because of bone marrow dry taps.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Cervantes F . How I treat myelofibrosis. Blood 2014; 124: 2635–2642.

    Article  CAS  PubMed  Google Scholar 

  2. Kroger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 2015; 29: 2126–2133.

    Article  CAS  PubMed  Google Scholar 

  3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895–2901.

    Article  CAS  PubMed  Google Scholar 

  4. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708.

    Article  CAS  PubMed  Google Scholar 

  5. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392–397.

    Article  PubMed  Google Scholar 

  6. Hernandez-Boluda JC, Pereira A, Gomez M, Boque C, Ferrer-Marin F, Raya JM et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica 2014; 99: e55–e57.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T et al. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 2017; 59: 110–116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 2017; e-pub ahead of print 31 May 2017 doi:10.1038/leu.2017.169.

    Article  CAS  PubMed  Google Scholar 

  9. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437–438.

    Article  CAS  PubMed  Google Scholar 

  10. Schemper M, Stare J . Explained variation in survival analysis. Stat Med 1996; 15: 1999–2012.

    Article  CAS  PubMed  Google Scholar 

  11. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761–770.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the Grant RD12/0036/0010 from the Instituto de Salud Carlos III, Spanish Ministry of Health.

Author information

Authors and Affiliations

  1. Hematology Department, Hospital Clínico, Valencia, Spain

    J-C Hernández-Boluda & M Gómez

  2. Transfusion Service, Hospital Clínic, Barcelona, Spain

    A Pereira

  3. Hematology Department, Hospital Clínic, Barcelona, Spain

    J-G Correa & F Cervantes

  4. Hematology Department, Hospital del Mar, Barcelona, Spain

    A Alvarez-Larrán

  5. Hematology and Medical Oncology Department, Hospital Morales Meseguer, Murcia, Spain

    F Ferrer-Marín

  6. Hematology Department, Hospital Universitario de Canarias, Tenerife, Spain

    J-M Raya

  7. Hematology Department, Hospital 12 de Octubre, Madrid, Spain

    J Martínez-López

  8. Hematology Department, Hospital Clínico, Santiago de Compostela, Spain

    M Pérez-Encinas

  9. Hematology Department, Hospital Germans Trias i Pujol, Badalona, Spain

    N Estrada

  10. Hematology Department, Hospital Duran i Reynals, Hospitalet de Llobregat, Spain

    P Velez

  11. Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain

    M-L Fox

  12. Hematology Department, Hospital Ramón y Cajal, Madrid, Spain

    V García-Gutiérrez

  13. Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain

    A Payer

  14. Hematology Department, Hospital La Paz, Madrid, Spain

    A Kerguelen

  15. Hematology Department, Hospital Universitario de Burgos, Burgos, Spain

    B Cuevas

  16. Hematology Department, Hospital Son Espases, Mallorca, Spain

    M-A Durán

  17. Hematology Department, Hospital de Jerez, Cádiz, Spain

    M-J Ramírez

  18. Hematology Department, Hospital Dr Negrín, Las Palmas de Gran Canaria, Spain

    M-T Gómez-Casares

  19. Hematology Department, Hospital Costa del Sol, Marbella, Spain

    M-I Mata-Vázquez

  20. Hematology Department, Hospital La Fe, Valencia, Spain

    E Mora

  21. Hematology Department, Hospital Sant Pau, Barcelona, Spain

    C Martínez-Valverde

Authors
  1. J-C Hernández-Boluda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J-G Correa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Alvarez-Larrán
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Ferrer-Marín
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J-M Raya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Martínez-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Pérez-Encinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Estrada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P Velez
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M-L Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. V García-Gutiérrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Payer
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Kerguelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. B Cuevas
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. M-A Durán
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M-J Ramírez
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. M-T Gómez-Casares
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. M-I Mata-Vázquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. E Mora
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. C Martínez-Valverde
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. M Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. F Cervantes
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)

Corresponding author

Correspondence to J-C Hernández-Boluda.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hernández-Boluda, JC., Pereira, A., Correa, JG. et al. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia 32, 553–555 (2018). https://doi.org/10.1038/leu.2017.297

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2017.297

This article is cited by

Search

Advanced search

Quick links